SCHEMBL23629606

SCHEMBL23629606

CC1C[C@@H](COC(=O)c2ccccc2)N(C(=O)O)C1=O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.52
CHRNA5 P30532 3/20 0.52
CHRNA7 P36544 3/20 0.52
CHRNA4 P43681 3/20 0.52
FOLH1 Q04609 3/20 0.45
NPC1 O15118 1/20 0.45
CES2 O00748 1/20 0.45
SCN1A P35498 1/20 0.44
SCN2A Q99250 1/20 0.44
SCN3A Q9NY46 1/20 0.44
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
PPM1B O75688 1/20 0.41
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30466112 0.86 CHRNB2 (0.46) CHRNB2CHRNA5CHRNA7CHRNA4FOLH1
SCHEMBL30466123 0.85 CHRNB2 (0.46) CHRNB2CHRNA5CHRNA7CHRNA4FOLH1
SCHEMBL23629617 0.76 CHRNB2 (0.54) CHRNB2CHRNA5CHRNA7CHRNA4FOLH1
SCHEMBL25281395 0.76 CHRNB2 (0.54) CHRNB2CHRNA5CHRNA7CHRNA4FOLH1
SCHEMBL23629616 0.74 CHRNB2 (0.52) CHRNB2CHRNA5CHRNA7CHRNA4NPC1
SCHEMBL30466113 0.73 CHRNB2 (0.54) CHRNB2CHRNA5CHRNA7CHRNA4NPC1
SCHEMBL25281113 0.73 CHRNB2 (0.54) CHRNB2CHRNA5CHRNA7CHRNA4NPC1
SCHEMBL19615663 0.71 CHRNB2 (0.52) CHRNB2CHRNA5CHRNA7CHRNA4FOLH1
SCHEMBL18588004 0.71 CHRNB2 (0.52) CHRNB2CHRNA5CHRNA7CHRNA4FOLH1
SCHEMBL18587701 0.71 CHRNB2 (0.52) CHRNB2CHRNA5CHRNA7CHRNA4FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023114200-A2 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2023-06-22 WO disclosed
EP-3847174-A1 MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS Achillion Pharmaceuticals, Inc. (US) 2021-07-14 EP disclosed